Showing results 1 to 20 of 75
next >
| Issue Date | Title | Author(s) |
| 2019 | All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china | Wei, Lai; Xu, Xiaoyuan; Guan, Yujuan; Zheng, Sujun; Sheng, Ji-Fang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Ji-Dong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojong; Zhang, Quan; Hu, Peng; Wang, Fu-Sheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei; Wu, Jinzi |
| Jul-2022 | ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis B patients with 24-week treatment of subcutaneous PD-L1 Ab ASC22 (Envafolimab) plus nucleos (t)ide analogs | Wang, Guiqiang; Cui, Yimin; Xie, Yao; Mao, Qianguo; Xie, Qing; Gu, Ye; Chen, Xin-Yue; Hu, Guoxin; Yang, Yongfeng; Lu, Jiajie; Zou, Guizhou; Zhang, Qin; Fu, Lei; Chen, Yongping; Guo, Xiaolin; Hou, Jinlin; Yan, Yuemei; He, Handan; Wu, Jinzi |
| Dec-2020 | aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis | Fan, Rong; Papatheodoridis, George; Sun, Jian; Innes, Hamish; Toyoda, Hidenori; Xie, Qing; Mo, Shuyuan; Sypsa, Vana; Guha, Indra Neil; Kumada, Takashi; Niu, Junqi; Dalekos, George; Yasuda, Satoshi; Barnes, Eleanor; Lian, Jianqi; Suri, Vithika; Idilman, Ramazan; Barclay, Stephen T.; Dou, Xiaoguang; Berg, Thomas; Hayes, Peter C.; Flaherty, John F.; Zhou, Yuanping; Zhang, Zhengang; Buti, Maria; Hutchinson, Sharon J.; Guo, Yabing; Calleja, Jose Luis; Lin, Lanjia; Zhao, Longfeng; Chen, Yongpeng; Janssen, Harry L. A.; Zhu, Chaonan; Shi, Lei; Tang, Xiaoping; Gaggar, Anuj; Wei, Lai; Jia, Jidong; Irving, William L.; Johnson, Philip J.; Lampertico, Pietro; Hou, Jinlin |
| Mar-2020 | Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy | Fan, Rong; Zhou, Bin; Xu, Min; Tan, Deming; Niu, Junqi; Wang, Hao; Ren, Hong; Chen, Xinyue; Wang, Maorong; Ning, Qin; Shi, Guangfeng; Sheng, Jifang; Tang, Hong; Bai, Xuefan; Liu, Shi; Lu, Fengmin; Peng, Jie; Sun, Jian; Xie, Qing; Hou, Jinlin; Wan, Mobin; Chen, Shijun; Yu, Yanyan; Ma, Hong; Cheng, Jun; Zhang, Hongfei; Liu, Huimin; Gao, Zhiliang; Sun Yat-Sen; Dou, Xiaoguang |
| 2018 | Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B | Yu, Rui; Tan, Deming; Ning, Qin; Niu, Junqi; Bai, Xuefan; Chen, Shijun; Cheng, Jun; Yu, Yanyan; Wang, Hao; Xu, Min; Shi, Guangfeng; Wan, Mobin; Chen, Xinyue; Tang, Hong; Sheng, Jifang; Dou, Xiaoguang; Shi, Junping; Ren, Hong; Wang, Maorong; Zhang, Hongfei; Gao, Zhiliang; Chen, Chengwei; Ma, Hong; Jia, Jidong; Hou, Jinlin; Xie, Qing; Sun, Jian |
| Jun-2021 | Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy | Fan, Rong; Niu, Junqi; Ma, Hong; Xie, Qing; Cheng, Jun; Rao, Huiying; Dou, Xiaoguang; Xie, Jianping; Zhao, Wei; Peng, Jie; Gao, Zhiliang; Gao, Hongbo; Chen, Xinyue; Chen, Jinjun; Li, Qiang; Tang, Hong; Zhang, Zhengang; Ren, Hong; Cheng, Mingliang; Liang, Xieer; Zhu, Chaonan; Wei, Lai; Jia, Jidong; Sun, Jian; Hou, Jinlin |
| 2018 | Baseline and Treatment Profiles of Patients Recruited in China Registry of Hepatitis B | Shan, Shan; You, Hong; Niu, Junqi; Shang, Jia; Zhang, Yuexin; Ren, Hong; Tang, Hong; Ding, Huiguo; Zhang, Lingyi; Nan, Yuemin; Han, Tao; Wang, Xiaozhong; Liu, Xiaoqing; Dou, Xiaoguang; Xu, Xiaoyuan; Wei, Lai; Hou, Jinlin; Duan, Zhongping; Zhuang, Hui; Kong, Yuanyuan; Jia, Jidong |
| 2018 | Baseline and Treatment Profiles of Patients Recruited in China Registry of Hepatitis B | Shan, Shan; You, Hong; Niu, Junqi; Shang, Jia; Zhang, Yuexin; Ren, Hong; Tang, Hong; Ding, Huiguo; Zhang, Lingyi; Nan, Yuemin; Han, Tao; Wang, Xiaozhong; Liu, Xiaoqing; Dou, Xiaoguang; Xu, Xiaoyuan; Wei, Lai; Hou, Jinlin; Duan, Zhongping; Zhuang, Hui; Kong, Yuanyuan; Jia, Jidong |
| 2013 | Baseline Quantitative Hepatitis B Core antibody is the Strongest Predictor for 2-year HBeAg seroconversion in HBeAg Positive CHB Patients Treated with Telbivudine Alone or Combined with Adefovir | Sun, Jian; Yuan, Quan; Xie, Qing; Fan, Rong; Tan, Deming; Ning, Qin; Niu, Junqi; Bai, Xuefan; Song, Liuwei; Chen, Shijun; Cheng, Jun; Yu, Yanyan; Wang, Hao; Xu, Min; Shi, Guangfeng; Wan, Mobin; Chen, Xin-Yue; Tang, Hong; Sheng, Jifang; Dou, Xiaoguang; Shi, Junping; Ren, Hong; Wang Maorong; Zhang, Hongfei; Gao, Zhiliang; Chen, Chengwei; Ma, Hong; Jia, Jidong; Xia, Ningshao; Hou, Jinlin |
| 2018 | Characterization of Serum HBV RNA in Patients with Untreated HBeAg-Positive and -Negative Chronic Hepatitis B Infection | Li, Yutang; He, Lingyuan; Li, Yao; Su, Mingze; Su, Jian; Hou, Jinlin; Deng, Juan; Wang, Shuai; Wang, Qiangyi; Xu, Xizhan; Zhuang, Hui; Li, Tong |
| Mar-2020 | China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B | Shan, Shan; Wei, Wei; Kong, Yuanyuan; Niu, Junqi; Shang, Jia; Xie, Wen; Zhang, Yuexin; Ren, Hong; Tang, Hong; Ding, Huiguo; Nan, Yuemin; Dou, Xiaoguang; Han, Tao; Xu, Xiaoyuan; Duan, Zhongping; Wei, Lai; Hou, Jinlin; Zhuang, Hui; You, Hong; Jia, Jidong |
| 2013 | Circulating Chemokine (C-X-C Motif) Receptor 5(+)CD4(+) T Cells Benefit Hepatitis B e Antigen Seroconversion Through IL-21 in Patients With Chronic Hepatitis B Virus Infection | Li, Yongyin; Ma, Shiwu; Tang, Libo; Li, Yun; Wang, Wei; Huang, Xuan; Lai, Qintao; Zhang, Mingxia; Sun, Jian; Li, Chris Kafai; Abbott, William G. H.; Naoumov, Nikolai V.; Zhang, Yu; Hou, Jinlin |
| 31-Dec-2024 | Circulating HBsAg-specific B cells are partially rescued in chronically HBV-infected patients with functional cure | Gu, Shuqin; Tang, Libo; Guo, Ling; Zhong, Chunxiu; Fu, Xin; Ye, Guofu; Zhong, Shihong; Li, Xiaoyi; Wen, Chunhua; Zhou, Yang; Wei, Jinling; Chen, Haitao; Novikov, Nikolai; Fletcher, Simon P.; Moody, M. Anthony; Hou, Jinlin; Li, Yongyin |
| 2015 | Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy | Zhou, Bin; Dong, Hui; He, Yungang; Sun, Jian; Jin, Weirong; Xie, Qing; Fan, Rong; Wang, Minxian; Li, Ran; Chen, Yangyi; Xie, Shaoqing; Shen, Yan; Huang, Xin; Wang, Shengyue; Lu, Fengming; Jia, Jidong; Zhuang, Hui; Locarnini, Stephen; Zhao, Guo-Ping; Jin, Li; Hou, Jinlin |
| 2014 | Current Challenges and the Management of Chronic Hepatitis C in Mainland China | Duan, Zhongping; Jia, Ji-Dong; Hou, Jinlin; Lou, Lillian; Tobias, Hillel; Xu, Xiao Yuan; Wei, Lai; Zhuang, Hui; Pan, Calvin Q. |
| 2017 | Demographic and baseline characteristics of patients in china registry of hepatitis B (CR-HEPB) | Kong, Yuanyuan; Wei, Lai; Hou, Jinlin; Duan, Zhongping; Zhuang, Hui; You, Hong; Jia, Jidong |
| Aug-2023 | Differential response of HBV envelope-specific CD4(+) T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy | Li, Yongyin; Wen, Chunhua; Gu, Shuqin; Wang, Weibin; Guo, Ling; Li, Chris Kafai; Yi, Xuan; Zhou, Yang; Dong, Zheyu; Fu, Xin; Zhong, Shihong; Wang, Yuhao; Huang, Kuiyuan; Yin, Junhua; Zhong, Chunxiu; Liang, Xieer; Fan, Rong; Chen, Haitao; Jiang, Deke; Zhang, Xiaoyong; Sun, Jian; Tang, Libo; Peng, Jie; Hou, Jinlin |
| 2019 | DOUBLE NEGATIVE HBV NUCLEIC ACID (DNA-/RNA-) PREDICTS OFF-TREATMENT DURABILITY OF NUCLES(T)IDE ANALOGUE IN A PROSPECTIVE COHORT | Fan, Rong; Zhou, Bin; Xu, Min; Tan, Deming; Niu, Junqi; Wang, Hao; Ren, Hong; Chen, Xinyue; Wang, Maorong; Ning, Qin; Shi, Guangfeng; Sheng, Jifang; Tang, Hong; Bai, Xuefan; Liu, Shi; Lu, Fengmin; Peng, Jie; Sun, Jian; Xie, Qing; Hou, Jinlin |
| Jul-2020 | Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis | Rao, Huiying; Yang, Xingxiang; Tan, Youwen; Ning, Qin; Yang, Daokun; Wang, Jiefei; Yang, Yongfeng; Zheng, Sujun; Yang, Dongliang; Hou, Jinlin; Xie, Qing; Zhao, Caiyan; Zhang, Lunli; Mao, Xiaorong; Sun, Tong; Bai, Lang; Zhang, Fuchun; Jin, Jinglan; Zhao, Yingren; Wang, Maorong; Xie, Wen; Ma, Yingjie; Quan, Jun; Yan, Xuebing; An, Ping; Lin, Feng; Jia, Jidong; Hu, Xiaoxuan; Gong, Zuojiong; Wu, Jie; Chen, Yongping; Jia, Zhansheng; Lin, Minghua; Wang, Guiqiang; Zhu, Yueyong; Zhang, Yingjun; Xie, Hongming; Luo, Lin; Ren, Qingyun; Huang, Rui; Wei, Lai |
| 2018 | Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China | Wei, Lai; Xu, Xiaoyun; Guan, Yujuan; Zheng, Sujun; Sheng, Jifang; Yang, Xingxiang; Ma, Yuanji; Huang, Yan; Kang, Yi; Wen, Xiaofeng; Li, Jun; Tan, Youwen; He, Qing; Xie, Qing; Wang, Maorong; An, Ping; Gong, Guozhong; Liu, Huimin; Ning, Qin; Hua, Rui; Ning, Bo; Xie, Wen; Zhang, Jiming; Huang, Wenxiang; Yang, Yongfeng; Lin, Minghua; Zhao, Yingren; Yu, Yanhong; Jia, Jidong; Yang, Dongliang; Chen, Liang; Ye, Yinong; Nan, Yuemin; Gong, Zuojiong; Zhang, Quan; Hu, Peng; Wang, FuSheng; Li, Yongguo; Li, Dongliang; Jia, Zhansheng; Hou, Jinlin; Chen, Chengwei |
